Drugs / GNKG168
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01743807 | Mar → Jul 2014 | acute lymphoblastic leukemia, acute myeloid leukemia | Therapeutic Advances in Childhood Leukemia Consortium | Terminated | No outcome recorded |
| Phase 1 | NCT01035216 | Sep 2009 → Nov 2013 | leukemia | SBI Biotech Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNKG168 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01743807 ↗ |
| Known as | CPG-685 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297962 ↗ |
| Action | Activate | “GNKG168 is a Toll-like receptor (TLR) agonist.” NCT01743807 ↗ |
| Modality | Oligonucleotide (other) | “CpG ODN” NCT01035216 ↗ |
| Route | Intravenous | “60 minute IV infusion” NCT01035216 ↗ |